|
1
|
Turcotte RE: Giant cell tumor of bone.
Orthop Clin North Am. 37:35–51. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Xu M, Song ZG, Xu CX, Rong GH, Fan KX,
Chen JY, Zhang W, Jia JP, Han G, Wang W, et al: IL-17A stimulates
the progression of giant cell tumors of bone. Clin Cancer Res.
19:4697–4705. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Müller DA, Beltrami G, Scoccianti G,
Campanacci DA, Franchi A and Capanna R: Risks and benefits of
combining denosumab and surgery in giant cell tumor of bone-a case
series. World J Surg Oncol. 14:2812016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Karpik M: Giant cell tumor (tumor
gigantocellularis, osteoclastoma)-epidemiology, diagnosis,
treatment. Ortop Traumatol Rehabil. 12:207–215. 2010.(In English,
Polish). PubMed/NCBI
|
|
5
|
Muramatsu K, Ihara K and Taguchi T:
Treatment of giant cell tumor of long bones: Clinical outcome and
reconstructive strategy for lower and upper limbs. Orthopedics.
32:4912009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Balke M, Schremper L, Gebert C, Ahrens H,
Streitbuerger A, Koehler G, Hardes J and Gosheger G: Giant cell
tumor of bone: Treatment and outcome of 214 cases. J Cancer Res
Clin Oncol. 134:969–978. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dominkus M, Ruggieri P, Bertoni F,
Briccoli A, Picci P, Rocca M and Mercuri M: Histologically verified
lung metastases in benign giant cell tumours-14 eases from a single
institution. Int Orthop. 30:499–504. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Van der Heijden L, Dijkstra PDS, Blay JY
and Gelderblom H: Giant cell tumour of bone in the denosumab era.
Eur J Cancer. 77:75–83. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yamamoto H, Iwasaki T, Yamada Y, Matsumoto
Y, Otsuka H, Yoshimoto M, Kohashi K, Taguchi K, Yokoyama R,
Nakashima Y and Oda Y: Diagnostic utility of histone H3.3 G34W,
G34R, and G34V mutant-specific antibodies for giant cell tumors of
bone. Hum Pathol. 73:41–50. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lankat-Buttgereit B and Göke R: The tumour
suppressor Pdcd4: Recent advances in the elucidation of function
and regulation. Biol Cell. 101:309–317. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yasuda M, Nishizawa T, Ohigashi H, Tanaka
T, Hou DX, Colburn NH and Murakami A: Linoleic acid metabolite
suppresses skin inflammation and tumor promotion in mice: Possible
roles of programmed cell death 4 induction. Carcinogenesis.
30:1209–1216. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hsu TC, Young MR, Cmarik J and Colburn NH:
Activator protein 1 (AP-1)- and nuclear factor kappaB
(NF-kappaB)-dependent transcriptional events in carcinogenesis.
Free Radic Biol Med. 28:1338–1348. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Loh PG, Yang HS, Walsh MA, Wang Q, Wang X,
Cheng Z, Liu D and Song H: Structural basis for translational
inhibition by the tumour suppressor Pdcd4. EMBO J. 28:274–285.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hilliard A, Hilliard B, Zheng SJ, Sun H,
Miwa T, Song W, Göke R and Chen YH: Translational regulation of
autoimmune inflammation and lymphoma genesis by programmed cell
death 4. J Immunol. 177:8095–8102. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jansen AP, Camalier CE and Colburn NH:
Epidermal expression of the translation inhibitor programmed cell
death 4 suppresses tumorigenesis. Cancer Res. 65:6034–6041. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang Z, Wang J, Li J, Wang X and Song W:
MicroRNA-150 promotes cell proliferation, migration, and invasion
of cervical cancer through targeting PDCD4. Biomed Pharmacother.
97:511–517. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hu X, Wang Y, Liang H, Fan Q, Zhu R, Cui
J, Zhang W, Zen K, Zhang CY, Hou D, et al: miR-23a/b promote tumor
growth and suppress apoptosis by targeting PDCD4 in gastric cancer.
Cell Death Dis. 8:e30592017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gao F, Zhang P, Zhou C, Li J, Wang Q, Zhu
F, Ma C, Sun W and Zhang L: Frequent loss of PDCD4 expression in
human glioma: Possible role in the tumorigenesis of glioma. Oncol
Rep. 17:123–128. 2007.PubMed/NCBI
|
|
19
|
Huang H, Wang X, Wang C, Zhuo L, Luo S and
Han S: The miR-93 promotes proliferation by directly targeting
PDCD4 in hepatocellular carcinoma. Neoplasma. 64:770–777. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ding L, Zhang X, Zhao M, Qu Z, Huang S,
Dong M and Gao F: An essential role of PDCD4 in progression and
malignant proliferation of gastrointestinal stromal tumors. Med
Oncol. 29:1758–1764. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang Y, Ding L, Zhang X, Zhao M, Qu Z,
Huang S, Zhang Y, Li Y and Gao F: Clinical significance of
programmed cell death 4 expression in malignant progression of
human nasal inverted papillomas. Med Oncol. 29:2505–2011. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Campanacci M, Baldini N, Boriani S and
Sudanese A: Giant-cell tumor of bone. J Bone Joint Surg Am.
69:106–114. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chadderton T, Wilson C, Bewick M and Glück
S: Evaluation of three rapid RNA extraction reagents: Relevance for
use in RT-PCR's and measurement of low level gene expression in
clinical samples. Cell Mol Biol (Noisy-le-grand). 43:1227–1234.
1997.PubMed/NCBI
|
|
24
|
Culley DE, Kovacik WP Jr, Brockman FJ and
Zhang W: Optimization of RNA isolation from the archaebacterium
Methanosarcina barkeri and validation for oligonucleotide
microarray analysis. J Microbiol Methods. 67:36–43. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Antal I, Sápi Z and Szendröi M: The
prognostic significance of DNA cytophotometry and proliferation
index (Ki-67) in giant cell tumors of bone. Int Orthop. 23:315–319.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Raskin KA, Schwab JH, Mankin HJ,
Springfield DS and Hornicek FJ: Giant cell tumor of bone. J Am Acad
Orthop Surg. 21:118–126. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gamberi G, Serra M, Ragazzini P, Magagnoli
G, Pazzaglia L, Ponticelli F, Ferrari C, Zanasi M, Bertoni F, Picci
P and Benassi MS: Identification of markers of possible prognostic
value in 57 giant cell tumors of bone. Oncol Rep. 10:351–356.
2003.PubMed/NCBI
|
|
28
|
Pennelli G, Galuppini F, Barollo S,
Cavedon E, Bertazza L, Fassan M, Guzzardo V, Pelizzo MR, Rugge M
and Mian C: The PDCD4/miR-21 pathway in medullary thyroid
carcinoma. Hum Pathol. 46:50–57. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fassan M, Pizzi M, Battaglia G, Giacomelli
L, Parente P, Bocus P, Ancona E and Rugge M: Programmed cell death
4 (PDCD4) expression during multistep Barrett's carcinogenesis. J
Clin Pathol. 63:692–696. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang WQ, Zhang H, Wang HB, Sun YG, Peng
ZH, Zhou G, Yang SM, Wang RQ and Fang DC: Programmed cell death 4
(PDCD4) enhances the sensitivity of gastric cancer cells to
TRAIL-induced apoptosis by inhibiting the PI3K/Akt signaling
pathway. Mol Diagn Ther. 14:155–161. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gao F, Wang X, Zhu F, Wang Q, Zhang X, Guo
C, Zhou C, Ma C, Sun W, Zhang Y, et al: PDCD4 gene silencing in
gliomas is associated with 5′CpG island methylation and
unfavourable prognosis. J Cell Mol Med. 13:4257–4267. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Briest F, Berndt A, Clement J, Junker K,
Eggeling Fv, Grimm S and Friedrich K: Tumor-stroma interactions in
tumorigenesis: Lessons from stem cell biology. Front Biosci (Elite
Ed). 4:1871–1887. 2012. View
Article : Google Scholar : PubMed/NCBI
|
